Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

Inclusion Criteria: * All patients with biopsy proven advanced melanoma are eligible if there is measurable disease. * Patients must have a life expectancy of at least 12 weeks. * Prior surgery, immunotherapy, minimal chemotherapy (1 drug for less than 4 months), or radiotherapy for primary tumor is acceptable but must be completed at least 4 weeks from study entry, and patient should have completely recovered from such procedures. * Patients must have a Zubrod performance status of 0-2. * Patients must sign an informed consent. * Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of ≥ 1500 cells/mm3, hemoglobin \> 8 g/dl, platelet count ≥ 100 000/mm3. * Patients should have a normal hepatic function with a total bilirubin \< 1.5 the upper limit of normal (ULN) and serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) \< 2 times the upper limit of normal (ULN),and adequate renal function as defined by a serum creatinine ≤ 1.5 times the ULN. * Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and at least for 3 months. * Patients with brain metastases are eligible if they have been appropriately treated, are asymptomatic Exclusion Criteria: * Pregnant women or nursing mothers are not eligible. * Patients must not receive any other concurrent chemotherapy or radiation during this trial. * Patients with severe medical problems that would interfere with the therapy are not eligible.